Share on StockTwits

Incyte (NASDAQ:INCY) EVP James M. Daly sold 11,111 shares of the stock on the open market in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $48.54, for a total value of $539,327.94. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Several analysts have recently commented on the stock. Analysts at Nomura reiterated a “buy” rating on shares of Incyte in a research note on Thursday. They now have a $90.00 price target on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Incyte in a research note on Friday, July 4th. They now have a $58.00 price target on the stock. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and twelve have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $62.80.

Incyte (NASDAQ:INCY) traded down 1.36% during mid-day trading on Friday, hitting $47.30. 568,365 shares of the company’s stock traded hands. Incyte has a one year low of $22.68 and a one year high of $70.86. The stock’s 50-day moving average is $52.63 and its 200-day moving average is $55.78. The company’s market cap is $7.929 billion.

Incyte (NASDAQ:INCY) last posted its quarterly earnings results on Thursday, May 1st. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by $0.04. The company had revenue of $89.80 million for the quarter, compared to the consensus estimate of $97.70 million. During the same quarter in the previous year, the company posted ($0.12) earnings per share. The company’s revenue for the quarter was up 26.3% on a year-over-year basis. On average, analysts predict that Incyte will post $-0.41 earnings per share for the current fiscal year.

Incyte Corporation (NASDAQ:INCY) is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat serious unmet medical needs.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.